TempraMed Receives Positive Response on Payor Reimbursement Model Driving Significant Return on Investment for Medical Payor Coverage

Executive Summary

• Independent validation of TempraMed’s payor ROI model by the Validation Institute, confirming significant cost‑savings for U.S. healthcare payors using VIVI Cap™ and VIVI Epi™.
• Validation supports launch of pilot programs with U.S. payors to demonstrate real‑world savings and accelerate reimbursement coverage.
• The validated economics create a scalable, reimbursement‑driven growth pathway, positioning TempraMed for broader adoption across health plans and high‑volume demand.

Key Details

• Validation Institute endorsement: Positive response on TempraMed’s payor reimbursement strategy; model meets/exceeds industry standards for healthcare economic analysis.
• Savings drivers identified: Reduced medication waste, fewer adverse clinical events, improved adherence, lower anxiety‑related utilization.
• Effective period: Validation effective through January 2027 and includes a $100,000 credibility guarantee.
• Pilot program plan: TempraMed to initiate payor pilot programs for covered patient populations to confirm real‑world savings; pilots aimed at national/regional health plans, employer‑sponsored plans, and value‑based integrated care organizations.
• Product focus: VIVI Cap™ (reusable temperature‑controlled cap) and VIVI Epi™ (temperature‑controlled epinephrine device) for insulin, GLP‑1 therapies, biologics, and emergency injectables.
• Management comments: CEO Ron Nagar highlighted the validation as a “major inflection point” that shifts discussions from assumptions to proven economics; GM Daniel Salomon emphasized potential to demonstrate reductions in drug waste and total cost of care.
• Investor implication: Validation creates upside potential for investors by establishing a credible, reimbursement‑driven growth pathway.

Notable Quotes

“This validation represents a major inflection point for TempraMed… independent, third‑party confirmation that VIVI Cap is not only meaningful for patients—but also economically compelling for payors.” – Ron Nagar, CEO, TempraMed

“Our discussions with payors are now grounded in validated economics, not assumptions.” – Ron Nagar, CEO, TempraMed

“Healthcare buyers are increasingly demanding proof, not promises… the economics demonstrate that payors covering this device can achieve rapid return on investment while improving outcomes for patients.” – Al Lewis, Founder & Validator‑In‑Chief, Validation Institute